vs
Amphastar Pharmaceuticals, Inc.（AMPH）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.2倍（$212.2M vs $183.1M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 13.3%，领先5.4%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs -1.8%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
AMPH vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.2倍
$183.1M
营收增速更快
RAMP
高出10.4%
-1.8%
净利率更高
RAMP
高出5.4%
13.3%
两年增速更快
RAMP
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $212.2M |
| 净利润 | $24.4M | $39.9M |
| 毛利率 | 46.8% | 71.9% |
| 营业利润率 | 19.4% | 18.6% |
| 净利率 | 13.3% | 18.8% |
| 营收同比 | -1.8% | 8.6% |
| 净利润同比 | -35.7% | 255.7% |
| 每股收益（稀释后） | $0.51 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRAMP
| Q4 25 | $183.1M | $212.2M | ||
| Q3 25 | $191.8M | $199.8M | ||
| Q2 25 | $174.4M | $194.8M | ||
| Q1 25 | $170.5M | $188.7M | ||
| Q4 24 | $186.5M | $195.4M | ||
| Q3 24 | $191.2M | $185.5M | ||
| Q2 24 | $182.4M | $176.0M | ||
| Q1 24 | $171.8M | $171.9M |
净利润AMPHRAMP
| Q4 25 | $24.4M | $39.9M | ||
| Q3 25 | $17.4M | $27.4M | ||
| Q2 25 | $31.0M | $7.7M | ||
| Q1 25 | $25.3M | $-6.3M | ||
| Q4 24 | $38.0M | $11.2M | ||
| Q3 24 | $40.4M | $1.7M | ||
| Q2 24 | $37.9M | $-7.5M | ||
| Q1 24 | $43.2M | $-5.4M |
毛利率AMPHRAMP
| Q4 25 | 46.8% | 71.9% | ||
| Q3 25 | 51.4% | 70.2% | ||
| Q2 25 | 49.6% | 70.1% | ||
| Q1 25 | 50.0% | 69.3% | ||
| Q4 24 | 46.5% | 71.9% | ||
| Q3 24 | 53.3% | 72.4% | ||
| Q2 24 | 52.2% | 70.6% | ||
| Q1 24 | 52.4% | 72.2% |
营业利润率AMPHRAMP
| Q4 25 | 19.4% | 18.6% | ||
| Q3 25 | 13.2% | 10.7% | ||
| Q2 25 | 24.2% | 3.7% | ||
| Q1 25 | 21.9% | -6.1% | ||
| Q4 24 | 24.2% | 7.5% | ||
| Q3 24 | 29.8% | 4.0% | ||
| Q2 24 | 30.3% | -3.0% | ||
| Q1 24 | 27.9% | -8.3% |
净利率AMPHRAMP
| Q4 25 | 13.3% | 18.8% | ||
| Q3 25 | 9.0% | 13.7% | ||
| Q2 25 | 17.8% | 4.0% | ||
| Q1 25 | 14.8% | -3.3% | ||
| Q4 24 | 20.4% | 5.7% | ||
| Q3 24 | 21.1% | 0.9% | ||
| Q2 24 | 20.8% | -4.3% | ||
| Q1 24 | 25.1% | -3.1% |
每股收益（稀释后）AMPHRAMP
| Q4 25 | $0.51 | $0.62 | ||
| Q3 25 | $0.37 | $0.42 | ||
| Q2 25 | $0.64 | $0.12 | ||
| Q1 25 | $0.51 | $-0.10 | ||
| Q4 24 | $0.74 | $0.17 | ||
| Q3 24 | $0.78 | $0.03 | ||
| Q2 24 | $0.73 | $-0.11 | ||
| Q1 24 | $0.81 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $403.4M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $962.3M |
| 总资产 | $1.6B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRAMP
| Q4 25 | $282.8M | $403.4M | ||
| Q3 25 | $276.2M | $376.9M | ||
| Q2 25 | $231.8M | $371.1M | ||
| Q1 25 | $236.9M | $420.8M | ||
| Q4 24 | $221.6M | $384.3M | ||
| Q3 24 | $250.5M | $348.4M | ||
| Q2 24 | $217.8M | $342.7M | ||
| Q1 24 | $289.6M | $368.9M |
总债务AMPHRAMP
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHRAMP
| Q4 25 | $788.8M | $962.3M | ||
| Q3 25 | $776.7M | $943.8M | ||
| Q2 25 | $757.5M | $947.8M | ||
| Q1 25 | $751.3M | $948.9M | ||
| Q4 24 | $732.3M | $957.7M | ||
| Q3 24 | $727.7M | $932.1M | ||
| Q2 24 | $713.3M | $951.9M | ||
| Q1 24 | $672.4M | $949.1M |
总资产AMPHRAMP
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
负债/权益比AMPHRAMP
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHRAMP
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $57.4M | ||
| Q2 25 | $35.6M | $-15.8M | ||
| Q1 25 | $35.1M | — | ||
| Q4 24 | $29.0M | $45.1M | ||
| Q3 24 | $60.0M | $55.6M | ||
| Q2 24 | $69.1M | $-9.3M | ||
| Q1 24 | $55.3M | — |
自由现金流AMPHRAMP
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $56.8M | ||
| Q2 25 | $25.0M | $-16.2M | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | $44.8M | ||
| Q3 24 | $46.2M | $55.4M | ||
| Q2 24 | $63.1M | $-9.6M | ||
| Q1 24 | $46.5M | — |
自由现金流率AMPHRAMP
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 28.4% | ||
| Q2 25 | 14.3% | -8.3% | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | 22.9% | ||
| Q3 24 | 24.1% | 29.8% | ||
| Q2 24 | 34.6% | -5.4% | ||
| Q1 24 | 27.1% | — |
资本支出强度AMPHRAMP
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.3% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.2% | ||
| Q4 24 | 6.7% | 0.1% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 1.0% |
现金转化率AMPHRAMP
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 2.09× | ||
| Q2 25 | 1.15× | -2.04× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 4.02× | ||
| Q3 24 | 1.48× | 32.10× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RAMP
暂无分部数据
